Identification

Name
Methotrimeprazine
Accession Number
DB01403
Type
Small Molecule
Groups
Approved, Investigational
Description

A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)

Structure
Thumb
Synonyms
  • (-)-(2R)-3-(2-Methoxy-10H-phenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine
  • (-)-10-(3-(Dimethylamino)-2-methylpropyl)-2-methoxyphenothiazine
  • 2-Methoxytrimeprazine
  • Levomepromazina
  • Levomepromazine
  • Levomepromazinum
  • Methotrimeprazine
External IDs
CL 36467 / CL 39743 / N05AA02 / RP 7044 / RP-7044 / SK&F 5116 / XP-03 / XP03
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MethoprazineTablet5 mgOralAa Pharma Inc1998-07-20Not applicableCanada
MethoprazineTablet50 mgOralAa Pharma Inc1998-07-20Not applicableCanada
MethoprazineTablet2 mgOralAa Pharma Inc1998-07-20Not applicableCanada
MethoprazineTablet25 mgOralAa Pharma Inc1998-07-20Not applicableCanada
Methotrimeprazine-2Tablet2 mgOralPro Doc Limitee1999-05-102009-07-23Canada
Methotrimeprazine-25Tablet25 mgOralPro Doc Limitee1999-05-122011-07-27Canada
Methotrimeprazine-5Tablet5 mgOralPro Doc Limitee1999-05-122011-07-27Canada
Methotrimeprazine-50Tablet50 mgOralPro Doc Limitee1999-05-102011-07-27Canada
Nov Meprazine Tab 50mgTablet50 mgOralNovopharm Limited1996-12-312005-08-10Canada
Novo Meprazine Tab 25mgTablet25 mgOralNovopharm Limited1996-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PMS-methotrimeprazineTablet50 mgOralPharmascience Inc1997-10-20Not applicableCanada
PMS-methotrimeprazineTablet25 mgOralPharmascience Inc1997-10-20Not applicableCanada
PMS-methotrimeprazineTablet5 mgOralPharmascience Inc1997-10-20Not applicableCanada
Riva-meprazine 25mg TabletsTablet25 mgOralLaboratoire Riva Inc1999-11-222003-07-28Canada
Riva-meprazine 50mg TabletsTablet50 mgOralLaboratoire Riva Inc1999-11-222003-07-28Canada
Riva-meprazine 5mg TabletsTablet5 mgOralLaboratoire Riva Inc1999-11-222003-07-28Canada
International/Other Brands
Levoprome / Neurocil / Nosinan / Nozinan
Categories
UNII
9G0LAW7ATQ
CAS number
60-99-1
Weight
Average: 328.472
Monoisotopic: 328.16093409
Chemical Formula
C19H24N2OS
InChI Key
VRQVVMDWGGWHTJ-CQSZACIVSA-N
InChI
InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1
IUPAC Name
[(2R)-3-(2-methoxy-10H-phenothiazin-10-yl)-2-methylpropyl]dimethylamine
SMILES
COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1

Pharmacology

Indication

For the treatment of psychosis, particular those of schizophrenia, and manic phases of bipolar disorder.

Associated Conditions
Associated Therapies
Pharmacodynamics

Methotrimeprazine is a phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)

Mechanism of action

Methotrimeprazine's antipsychotic effect is largely due to its antagonism of dopamine receptors in the brain. In addition, its binding to 5HT2 receptors may also play a role.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
UD(1A) dopamine receptor
antagonist
Human
UD(1B) dopamine receptor
antagonist
Human
UD(3) dopamine receptor
antagonist
Human
UD(4) dopamine receptor
antagonist
Human
U5-hydroxytryptamine receptor 2A
antagonist
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
UHistamine H1 receptor
antagonist
Human
UMuscarinic acetylcholine receptor M1
antagonist
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
UMuscarinic acetylcholine receptor M3
antagonist
Human
UMuscarinic acetylcholine receptor M4
antagonist
Human
UMuscarinic acetylcholine receptor M5
antagonist
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
UAlpha-1D adrenergic receptor
antagonist
Human
UAlpha-2A adrenergic receptor
antagonist
Human
UAlpha-2B adrenergic receptor
antagonist
Human
UAlpha-2C adrenergic receptor
antagonist
Human
Absorption

Methotrimeprazine has an incomplete oral bioavailability, because it undergoes considerable first-pass-metabolism in the liver. Oral bioavailability is approximately 50 to 60%.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic. Methotrimeprazine is metabolized in the liver and degraded to a sulfoxid-, a glucuronid- and a demethyl-moiety.

Route of elimination
Not Available
Half life

Approximately 20 hours.

Clearance
Not Available
Toxicity

Symptoms of overdose include convulsions, spastic movements, and coma.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Methotrimeprazine.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Methotrimeprazine.Investigational
2,5-Dimethoxy-4-ethylamphetamineMethotrimeprazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineMethotrimeprazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineMethotrimeprazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineMethotrimeprazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Methotrimeprazine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Methotrimeprazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-Nitroindazole7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
AbirateroneThe serum concentration of Methotrimeprazine can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Approved, Investigational
AcepromazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
AceprometazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Methotrimeprazine.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational, Withdrawn
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Methotrimeprazine.Approved
AdipiplonAdipiplon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
AdrafinilMethotrimeprazine may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineMethotrimeprazine may decrease the vasoconstricting activities of Agmatine.Experimental, Investigational
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Methotrimeprazine.Experimental, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Methotrimeprazine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Alaproclate.Experimental
AlfaxaloneAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Methotrimeprazine.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Methotrimeprazine.Investigational
AllopregnanoloneAllopregnanolone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Methotrimeprazine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Methotrimeprazine.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlphacetylmethadolAlphacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental, Illicit
AlphaprodineAlphaprodine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Illicit
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Methotrimeprazine.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AmantadineThe therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Amantadine.Approved
AmibegronMethotrimeprazine may decrease the vasoconstricting activities of Amibegron.Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Methotrimeprazine.Approved, Withdrawn
AmiodaroneThe metabolism of Methotrimeprazine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideMethotrimeprazine may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitrazMethotrimeprazine may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
AmlodipineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
AmodiaquineThe serum concentration of Methotrimeprazine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
AmperozideAmperozide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Methotrimeprazine.Approved, Illicit, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Methotrimeprazine.Approved, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Amrinone.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Methotrimeprazine.Approved, Investigational
AnagrelideMethotrimeprazine may increase the QTc-prolonging activities of Anagrelide.Approved
AnisodamineMethotrimeprazine may decrease the vasoconstricting activities of Anisodamine.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Methotrimeprazine.Approved, Investigational
ApomorphineThe therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Apomorphine.Approved, Investigational
ApraclonidineMethotrimeprazine may decrease the vasoconstricting activities of Apraclonidine.Approved
AprindineThe metabolism of Aprindine can be decreased when combined with Methotrimeprazine.Approved
AranidipineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Aranidipine.Approved, Investigational
ArbutamineMethotrimeprazine may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Methotrimeprazine.Approved, Investigational
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Investigational
Arsenic trioxideMethotrimeprazine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Methotrimeprazine.Approved
ArtemisininThe serum concentration of Methotrimeprazine can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Methotrimeprazine can be increased when it is combined with Artemotil.Approved
ArtenimolThe serum concentration of Methotrimeprazine can be increased when it is combined with Artenimol.Approved, Investigational
ArtesunateThe serum concentration of Methotrimeprazine can be increased when it is combined with Artesunate.Approved, Investigational
ArticaineArticaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Methotrimeprazine.Approved, Withdrawn
AsunaprevirThe metabolism of Asunaprevir can be decreased when combined with Methotrimeprazine.Approved, Investigational, Withdrawn
AtenololAtenolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Approved
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Methotrimeprazine.Approved
AtovaquoneThe serum concentration of Methotrimeprazine can be increased when it is combined with Atovaquone.Approved
AvanafilAvanafil may increase the hypotensive activities of Methotrimeprazine.Approved
AzaperoneAzaperone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational, Vet Approved
AzelastineMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Azimilide.Investigational
AzithromycinMethotrimeprazine may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Methotrimeprazine.Investigational
BambuterolMethotrimeprazine may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Illicit
BarnidipineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Barnidipine.Approved
BedaquilineMethotrimeprazine may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Experimental
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Methotrimeprazine.Investigational
BencyclaneThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Bencyclane.Experimental
BenidipineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Benidipine.Approved, Investigational
BenperidolBenperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Methotrimeprazine.Approved
BenzocaineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
BenzphetamineMethotrimeprazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
Benzylpenicilloyl PolylysineMethotrimeprazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Methotrimeprazine.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
BetaxololThe metabolism of Betaxolol can be decreased when combined with Methotrimeprazine.Approved, Investigational
BevantololMethotrimeprazine may increase the antihypertensive activities of Bevantolol.Approved
BezitramideMethotrimeprazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
BioallethrinThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Bioallethrin.Approved, Experimental
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Methotrimeprazine.Approved
BitolterolMethotrimeprazine may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Approved
BortezomibThe metabolism of Bortezomib can be decreased when combined with Methotrimeprazine.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Methotrimeprazine.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational
BromisovalBromisoval may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
BromocriptineThe therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
BromperidolBromperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
BrotizolamBrotizolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational, Withdrawn
BucindololBucindolol may increase the antihypertensive activities of Methotrimeprazine.Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Methotrimeprazine.Investigational, Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Methotrimeprazine.Experimental, Investigational
BunazosinBunazosin may increase the antihypertensive activities of Methotrimeprazine.Investigational
BupivacaineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Approved
BuprenorphineBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Methotrimeprazine can be decreased when combined with Bupropion.Approved
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
ButacaineButacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
ButalbitalButalbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
ButambenButamben may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Withdrawn
ButethalButethal may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Methotrimeprazine.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Methotrimeprazine.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium silicateCalcium silicate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methotrimeprazine.Approved
CanertinibCanertinib may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Methotrimeprazine.Approved
CarbamazepineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Carboxyamidotriazole.Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Methotrimeprazine.Experimental
CarfentanilCarfentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Methotrimeprazine.Approved, Investigational
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
CaroverineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Caroverine.Experimental
CarteololThe metabolism of Carteolol can be decreased when combined with Methotrimeprazine.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Methotrimeprazine.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Methotrimeprazine.Experimental
CelecoxibThe metabolism of Methotrimeprazine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Methotrimeprazine.Approved, Investigational, Vet Approved
CeritinibMethotrimeprazine may increase the QTc-prolonging activities of Ceritinib.Approved
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Methotrimeprazine.Approved
Chloral hydrateChloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational
ChlormezanoneChlormezanone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational, Withdrawn
ChloroprocaineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Methotrimeprazine.Approved, Investigational, Vet Approved
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ChlorphentermineMethotrimeprazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproguanilThe serum concentration of Methotrimeprazine can be increased when it is combined with Chlorproguanil.Investigational
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
ChlorprothixeneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational, Withdrawn
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
CholecalciferolThe metabolism of Methotrimeprazine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Methotrimeprazine.Experimental
CilnidipineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Cilnidipine.Approved, Investigational
CilostazolThe metabolism of Cilostazol can be decreased when combined with Methotrimeprazine.Approved, Investigational
CimetidineThe metabolism of Methotrimeprazine can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Methotrimeprazine can be decreased when combined with Cinacalcet.Approved
CinchocaineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Methotrimeprazine.Approved, Investigational
CiprofloxacinMethotrimeprazine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CirazolineMethotrimeprazine may decrease the vasoconstricting activities of Cirazoline.Experimental
CisaprideMethotrimeprazine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Citalopram can be decreased when combined with Methotrimeprazine.Approved
ClarithromycinMethotrimeprazine may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
ClenbuterolMethotrimeprazine may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Methotrimeprazine.Approved, Investigational
ClidiniumClidinium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
clomethiazoleclomethiazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational, Vet Approved
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
ClonidineClonidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ClopenthixolClopenthixol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
CloranololCloranolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Experimental
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
ClothiapineClothiapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
ClotrimazoleThe metabolism of Methotrimeprazine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
CobicistatThe serum concentration of Methotrimeprazine can be increased when it is combined with Cobicistat.Approved
CocaineCocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
CodeineCodeine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
CrizotinibMethotrimeprazine may increase the QTc-prolonging activities of Crizotinib.Approved
CurcuminThe metabolism of Methotrimeprazine can be decreased when combined with Curcumin.Approved, Investigational
CyclandelateThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Cyclandelate.Approved
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
Cycloguanil embonateThe serum concentration of Methotrimeprazine can be increased when it is combined with Cycloguanil embonate.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Methotrimeprazine.Approved, Investigational
CyclopropaneCyclopropane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Methotrimeprazine.Approved
DapiprazoleDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Methotrimeprazine.Investigational
DapsoneThe serum concentration of Methotrimeprazine can be increased when it is combined with Dapsone.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Methotrimeprazine.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Darodipine.Experimental
DarunavirThe serum concentration of Methotrimeprazine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Methotrimeprazine.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Methotrimeprazine.Approved, Investigational
DelamanidMethotrimeprazine may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DelavirdineThe metabolism of Methotrimeprazine can be decreased when combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Methotrimeprazine.Investigational
DeramciclaneDeramciclane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Desvenlafaxine.Approved, Investigational
DetomidineDetomidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
DeutetrabenazineMethotrimeprazine may increase the QTc-prolonging activities of Deutetrabenazine.Approved, Investigational
DexbrompheniramineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Methotrimeprazine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Methotrimeprazine.Approved, Illicit, Investigational, Withdrawn
DexmedetomidineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Methotrimeprazine.Approved, Investigational
DextroamphetamineMethotrimeprazine may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Methotrimeprazine.Approved
DextromoramideDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational, Vet Approved
Diethyl etherDiethyl ether may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
DiethylpropionMethotrimeprazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinDifenoxin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
DihydrocodeineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Methotrimeprazine.Approved, Investigational
DihydroetorphineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental, Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Methotrimeprazine.Approved, Investigational
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
DiphenoxylateDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
DipivefrinMethotrimeprazine may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Methotrimeprazine.Approved
DisopyramideMethotrimeprazine may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineDixyrazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
DL-MethylephedrineMethotrimeprazine may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineMethotrimeprazine may decrease the vasoconstricting activities of Dobutamine.Approved
DofetilideMethotrimeprazine may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Methotrimeprazine.Approved, Investigational
DomperidoneThe metabolism of Domperidone can be decreased when combined with Methotrimeprazine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Methotrimeprazine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Methotrimeprazine.Approved
DopexamineMethotrimeprazine may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DoramectinDoramectin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
DosulepinThe metabolism of Methotrimeprazine can be decreased when combined with Dosulepin.Approved
DotarizineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Methotrimeprazine.Approved
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
DoxofyllineMethotrimeprazine may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Methotrimeprazine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Methotrimeprazine.Approved, Investigational
DoxycyclineThe serum concentration of Methotrimeprazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
DPDPEDPDPE may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
DronedaroneMethotrimeprazine may increase the antihypertensive activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
DrotebanolDrotebanol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental, Illicit
DroxidopaMethotrimeprazine may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Methotrimeprazine.Approved
DyclonineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
EcgonineEcgonine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental, Illicit
EcopipamEcopipam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
EfavirenzEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
EfonidipineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Efonidipine.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Methotrimeprazine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Methotrimeprazine.Approved
EltanoloneEltanolone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Methotrimeprazine.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Methotrimeprazine.Approved, Investigational
EncainideThe metabolism of Encainide can be decreased when combined with Methotrimeprazine.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Methotrimeprazine.Investigational
EnfluraneEnflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational, Vet Approved
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Methotrimeprazine.Experimental
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
EpanololEpanolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Experimental
EperisoneThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Eperisone.Approved, Investigational
EphedraMethotrimeprazine may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineMethotrimeprazine may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Methotrimeprazine.Approved, Investigational
EpinephrineMethotrimeprazine may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Methotrimeprazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Methotrimeprazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Methotrimeprazine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Methotrimeprazine.Approved, Investigational
ErythromycinMethotrimeprazine may increase the QTc-prolonging activities of Erythromycin.Approved, Investigational, Vet Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Experimental
EscitalopramMethotrimeprazine may increase the antihypertensive activities of Escitalopram.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Methotrimeprazine.Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Approved
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
EtafedrineMethotrimeprazine may decrease the vasoconstricting activities of Etafedrine.Approved
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
EthchlorvynolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Withdrawn
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
Ethyl carbamateEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Withdrawn
Ethyl chlorideEthyl chloride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Experimental, Investigational
Ethyl loflazepateEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
EthylmorphineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
EtidocaineEtidocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
EtifoxineEtifoxine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational, Withdrawn
EtilefrineMethotrimeprazine may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtizolamEtizolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
EtomidateEtomidate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Etoperidone.Withdrawn
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Methotrimeprazine.Approved, Investigational
EtorphineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Illicit, Vet Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
FelodipineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Felodipine.Approved, Investigational
FencamfamineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Withdrawn
FendilineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Fendiline.Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoterolMethotrimeprazine may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methotrimeprazine.Approved
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
FingolimodThe metabolism of Fingolimod can be decreased when combined with Methotrimeprazine.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Fish oil.Approved, Nutraceutical
FlecainideThe metabolism of Flecainide can be decreased when combined with Methotrimeprazine.Approved, Withdrawn
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
FluanisoneFluanisone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Methotrimeprazine.Approved, Vet Approved
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational, Withdrawn
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational
FluspirileneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
Fluticasone propionateFluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Methotrimeprazine.Approved
FluvoxamineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Methotrimeprazine.Approved, Investigational
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
FospropofolFospropofol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Methotrimeprazine.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Methotrimeprazine.Approved, Investigational
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
Gabapentin EnacarbilGabapentin Enacarbil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
Gadobenic acidMethotrimeprazine may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Methotrimeprazine.Approved
GallopamilThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Gallopamil.Investigational
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Methotrimeprazine.Approved, Investigational
GemifloxacinMethotrimeprazine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineMethotrimeprazine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeGepirone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Methotrimeprazine.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Methotrimeprazine.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Methotrimeprazine.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
GlutethimideGlutethimide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Methotrimeprazine.Approved
GoserelinMethotrimeprazine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Methotrimeprazine.Approved, Investigational
GuanabenzMethotrimeprazine may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Methotrimeprazine.Investigational
HalazepamHalazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Methotrimeprazine.Approved
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
HalothaneHalothane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
HeroinHeroin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
HexoprenalineMethotrimeprazine may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineMethotrimeprazine may decrease the vasoconstricting activities of Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
HydrocodoneMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
HydroxyamphetamineMethotrimeprazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxychloroquineThe serum concentration of Methotrimeprazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Methotrimeprazine.Approved
IbutilideMethotrimeprazine may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Methotrimeprazine.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Methotrimeprazine.Approved
ImatinibThe metabolism of Imatinib can be decreased when combined with Methotrimeprazine.Approved
ImipramineImipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
IndacaterolMethotrimeprazine may decrease the vasoconstricting activities of Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Indalpine.Investigational, Withdrawn
IndenololIndenolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Withdrawn
IndinavirThe metabolism of Methotrimeprazine can be decreased when combined with Indinavir.Approved
IndiplonIndiplon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
IndoraminIndoramin may increase the antihypertensive activities of Methotrimeprazine.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Methotrimeprazine.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Methotrimeprazine.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Methotrimeprazine.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Methotrimeprazine.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methotrimeprazine.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Methotrimeprazine.Approved
Iofetamine I-123Methotrimeprazine may decrease the stimulatory activities of Iofetamine I-123.Approved
IpecacThe metabolism of Ipecac can be decreased when combined with Methotrimeprazine.Approved, Withdrawn
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Methotrimeprazine.Approved
IsocarboxazidThe therapeutic efficacy of Methotrimeprazine can be increased when used in combination with Isocarboxazid.Approved
IsoetarineMethotrimeprazine may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
IsomethepteneMethotrimeprazine may decrease the vasoconstricting activities of Isometheptene.Approved
IsoniazidThe metabolism of Methotrimeprazine can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineMethotrimeprazine may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxsuprineMethotrimeprazine may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Isradipine.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Methotrimeprazine.Approved, Investigational
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
KetazolamKetazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
KetobemidoneKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
KetoconazoleThe metabolism of Methotrimeprazine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Methotrimeprazine.Approved
LacidipineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Lacidipine.Approved, Investigational
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Investigational
LenvatinibMethotrimeprazine may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LercanidipineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Lercanidipine.Approved, Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Methotrimeprazine.Approved, Investigational
LeuprolideMethotrimeprazine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Approved, Investigational
LevobunololMethotrimeprazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineLevobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
LevodopaLevodopa may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
LevofloxacinMethotrimeprazine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Methotrimeprazine.Approved, Investigational
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
LevosalbutamolMethotrimeprazine may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LidocaineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Lidoflazine.Experimental
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Methotrimeprazine.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Methotrimeprazine.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Methotrimeprazine.Approved
LisdexamfetamineMethotrimeprazine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Methotrimeprazine.Approved, Investigational
LithiumLithium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
LofentanilLofentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Illicit
LofexidineThe therapeutic efficacy of Methotrimeprazine can be increased when used in combination with Lofexidine.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Methotrimeprazine.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Methotrimeprazine.Approved
LopinavirThe metabolism of Methotrimeprazine can be decreased when combined with Lopinavir.Approved
LoprazolamLoprazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Methotrimeprazine.Approved
LormetazepamLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
LorpiprazoleThe metabolism of Lorpiprazole can be decreased when combined with Methotrimeprazine.Approved
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
LumefantrineMethotrimeprazine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MacimorelinMethotrimeprazine may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateMagnesium sulfate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineThe metabolism of Methotrimeprazine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MebicarMebicar may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MedazepamMedazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
MedetomidineMedetomidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
MefloquineThe serum concentration of Methotrimeprazine can be increased when it is combined with Mefloquine.Approved, Investigational
MelatoninMelatonin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Nutraceutical, Vet Approved
MelperoneMelperone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Menthol.Approved
MephedroneMethotrimeprazine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineMethotrimeprazine may decrease the stimulatory activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Methotrimeprazine.Investigational, Withdrawn
MepindololMepindolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Experimental
MepivacaineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
MeptazinolMeptazinol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Methotrimeprazine.Approved
MesoridazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MetaraminolMethotrimeprazine may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Methotrimeprazine.Approved
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
Methadyl AcetateMethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Methotrimeprazine.Approved, Illicit
MethapyrileneMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Withdrawn
MethaqualoneMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Illicit, Withdrawn
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxamineMethotrimeprazine may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyfluraneMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational, Vet Approved
MethoxyphenamineMethotrimeprazine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethyldopaMethotrimeprazine may decrease the vasoconstricting activities of Methyldopa.Approved
MethylecgonineMethylecgonine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Methotrimeprazine.Approved, Illicit, Withdrawn
MetipranololMethotrimeprazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Methotrimeprazine.Approved, Investigational
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Methotrimeprazine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Methotrimeprazine.Approved, Investigational
MetyrosineMethotrimeprazine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Methotrimeprazine.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Methotrimeprazine.Approved, Investigational
MibefradilThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Mibefradil.Investigational, Withdrawn
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
MidodrineMethotrimeprazine may decrease the vasoconstricting activities of Midodrine.Approved
MidomafetamineMethotrimeprazine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Methotrimeprazine can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneMifepristone may increase the QTc-prolonging activities of Methotrimeprazine.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Methotrimeprazine.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Methotrimeprazine.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Milnacipran.Approved, Investigational
MinaprineThe metabolism of Minaprine can be decreased when combined with Methotrimeprazine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be decreased when combined with Methotrimeprazine.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Methotrimeprazine.Investigational
MirtazapineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
MizoribineThe serum concentration of Methotrimeprazine can be increased when it is combined with Mizoribine.Investigational
MMDAMethotrimeprazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Methotrimeprazine.Approved, Investigational
MolindoneMolindone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MoxifloxacinMethotrimeprazine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineMethotrimeprazine may decrease the vasoconstricting activities of Moxonidine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Approved
NaftopidilThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Naftopidil.Investigational
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
NaphazolineMethotrimeprazine may decrease the vasoconstricting activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Methotrimeprazine.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Methotrimeprazine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Methotrimeprazine.Approved, Investigational
NefazodoneNefazodone may increase the antihypertensive activities of Methotrimeprazine.Approved, Withdrawn
NetupitantThe metabolism of Netupitant can be decreased when combined with Methotrimeprazine.Approved, Investigational
NevirapineThe metabolism of Nevirapine can be decreased when combined with Methotrimeprazine.Approved
NicardipineMethotrimeprazine may increase the antihypertensive activities of Nicardipine.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Methotrimeprazine.Approved, Investigational
NicomorphineMethotrimeprazine may increase the hypotensive activities of Nicomorphine.Experimental
NicotineThe metabolism of Nicotine can be decreased when combined with Methotrimeprazine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Methotrimeprazine.Approved
NiguldipineMethotrimeprazine may increase the antihypertensive activities of Niguldipine.Experimental
NilotinibMethotrimeprazine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Nisoldipine.Approved
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
NitrendipineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Nitrendipine.Approved, Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Methotrimeprazine.Approved, Investigational, Vet Approved
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
NordazepamNordazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
NorepinephrineMethotrimeprazine may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineMethotrimeprazine may decrease the vasoconstricting activities of Norfenefrine.Experimental
NorfluraneNorflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
NormethadoneNormethadone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
NylidrinMethotrimeprazine may decrease the vasoconstricting activities of Nylidrin.Approved
OctopamineMethotrimeprazine may decrease the vasoconstricting activities of Octopamine.Experimental
OfloxacinMethotrimeprazine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
OlodaterolMethotrimeprazine may decrease the vasoconstricting activities of Olodaterol.Approved
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
OndansetronOndansetron may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
OpiumOpium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
OrciprenalineMethotrimeprazine may decrease the vasoconstricting activities of Orciprenaline.Approved
OrphenadrineMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantOsanetant may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
OtiloniumThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Otilonium.Experimental, Investigational
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
OxprenololOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
OxybuprocaineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational
OxyfedrineMethotrimeprazine may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineMethotrimeprazine may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational, Vet Approved
PaliperidonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Methotrimeprazine.Approved, Investigational
PanobinostatThe serum concentration of Methotrimeprazine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeParaldehyde may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
ParoxetineThe metabolism of Methotrimeprazine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Methotrimeprazine.Approved
Peginterferon alfa-2bThe serum concentration of Methotrimeprazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Approved, Investigational
PenfluridolPenfluridol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
PentamidineThe metabolism of Pentamidine can be decreased when combined with Methotrimeprazine.Approved, Investigational
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Methotrimeprazine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PerazinePerazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
PerflutrenMethotrimeprazine may increase the QTc-prolonging activities of Perflutren.Approved
PergolideMethotrimeprazine may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Methotrimeprazine.Approved, Investigational
PerospironePerospirone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Methotrimeprazine.Withdrawn
PhenazocinePhenazocine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
PhendimetrazineMethotrimeprazine may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Methotrimeprazine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Methotrimeprazine.Approved, Investigational, Withdrawn
PhenibutPhenibut may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
PhenoperidinePhenoperidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Methotrimeprazine.Approved
PhenoxyethanolPhenoxyethanol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PhentermineMethotrimeprazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineMethotrimeprazine may increase the antihypertensive activities of Phentolamine.Approved
PhenylephrineMethotrimeprazine may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineMethotrimeprazine may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
PimozidePimozide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PinaveriumThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Pinaverium.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Methotrimeprazine.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
PipamperonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
PiperaquineThe serum concentration of Methotrimeprazine can be increased when it is combined with Piperaquine.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Methotrimeprazine.Approved, Vet Approved
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
PirbuterolMethotrimeprazine may decrease the vasoconstricting activities of Pirbuterol.Approved
PiribedilThe therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Piribedil.Investigational
PiritramidePiritramide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Methotrimeprazine.Approved, Investigational
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Methotrimeprazine.Experimental
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Methotrimeprazine.Approved, Investigational
PractololPractolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Approved
PramipexoleMethotrimeprazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
PramocainePramocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
PrazosinPrazosin may increase the antihypertensive activities of Methotrimeprazine.Approved
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational
PrenalterolMethotrimeprazine may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Prenylamine.Withdrawn
PrilocainePrilocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PrimaquineThe serum concentration of Methotrimeprazine can be increased when it is combined with Primaquine.Approved
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Methotrimeprazine.Approved
ProcaineProcaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Methotrimeprazine.Approved, Investigational
ProcaterolMethotrimeprazine may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Methotrimeprazine.Approved, Vet Approved
ProguanilThe serum concentration of Methotrimeprazine can be increased when it is combined with Proguanil.Approved
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Methotrimeprazine.Approved
PropanididPropanidid may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
ProparacaineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
PropericiazineMethotrimeprazine may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePropiomazine may increase the antihypertensive activities of Methotrimeprazine.Approved
PropiverineMethotrimeprazine may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational, Vet Approved
PropoxycainePropoxycaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Methotrimeprazine.Approved, Investigational
ProtokylolMethotrimeprazine may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ProxibarbalProxibarbal may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
PSD502PSD502 may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Methotrimeprazine.Approved
PyrimethamineThe serum concentration of Methotrimeprazine can be increased when it is combined with Pyrimethamine.Approved, Investigational, Vet Approved
PyronaridineThe serum concentration of Methotrimeprazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
QuinacrineThe serum concentration of Methotrimeprazine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
QuinidineMethotrimeprazine may increase the antihypertensive activities of Quinidine.Approved, Investigational
QuinineThe metabolism of Quinine can be decreased when combined with Methotrimeprazine.Approved
QuinisocaineQuinisocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
RacepinephrineMethotrimeprazine may increase the antihypertensive activities of Racepinephrine.Approved
RacloprideRaclopride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
RactopamineMethotrimeprazine may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RadicicolThe serum concentration of Methotrimeprazine can be increased when it is combined with Radicicol.Experimental
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Methotrimeprazine.Approved
RanolazineThe metabolism of Methotrimeprazine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Methotrimeprazine.Approved
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
RemoxiprideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
RepinotanThe metabolism of Repinotan can be decreased when combined with Methotrimeprazine.Investigational
ReproterolMethotrimeprazine may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Methotrimeprazine.Approved, Investigational
RilmenidineMethotrimeprazine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RimiterolMethotrimeprazine may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
RitanserinRitanserin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
RitobegronMethotrimeprazine may decrease the stimulatory activities of Ritobegron.Investigational
RitodrineMethotrimeprazine may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RitonavirThe metabolism of Methotrimeprazine can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Methotrimeprazine.Approved
RolapitantThe metabolism of Methotrimeprazine can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineRomifidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
RopiniroleMethotrimeprazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
RotigotineMethotrimeprazine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Methotrimeprazine.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methotrimeprazine.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Methotrimeprazine.Approved
SalbutamolMethotrimeprazine may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolMethotrimeprazine may decrease the vasoconstricting activities of Salmeterol.Approved
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Methotrimeprazine.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Methotrimeprazine.Approved
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Methotrimeprazine.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Seletracetam.Investigational
SepranoloneSepranolone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
SertindoleSertindole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Methotrimeprazine.Approved
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Methotrimeprazine.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Methotrimeprazine.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Methotrimeprazine.Approved
SinefunginThe serum concentration of Methotrimeprazine can be increased when it is combined with Sinefungin.Experimental
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
SolabegronMethotrimeprazine may decrease the vasoconstricting activities of Solabegron.Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Methotrimeprazine.Investigational
SotalolMethotrimeprazine may increase the QTc-prolonging activities of Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Methotrimeprazine.Experimental
StiripentolStiripentol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
SulfadoxineThe serum concentration of Methotrimeprazine can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfametopyrazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulfisoxazoleMethotrimeprazine may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
SulpirideMethotrimeprazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideSultopride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Methotrimeprazine.Approved, Investigational
SuvorexantMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SynephrineMethotrimeprazine may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Methotrimeprazine.Approved, Investigational
TafenoquineThe serum concentration of Methotrimeprazine can be increased when it is combined with Tafenoquine.Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Methotrimeprazine.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Methotrimeprazine.Approved, Investigational
TandospironeTandospirone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Methotrimeprazine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Methotrimeprazine.Approved, Investigational, Withdrawn
TelavancinMethotrimeprazine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinMethotrimeprazine may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Methotrimeprazine.Approved
TerbinafineThe metabolism of Methotrimeprazine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Methotrimeprazine.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Methotrimeprazine.Approved, Withdrawn
TerodilineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Methotrimeprazine.Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Methotrimeprazine.Approved, Investigational
TetracaineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
TetrahydropalmatineTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
TetrodotoxinTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Investigational
TetryzolineMethotrimeprazine may decrease the vasoconstricting activities of Tetryzoline.Approved
ThalidomideMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Methotrimeprazine.Approved
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
ThioproperazineMethotrimeprazine may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Methotrimeprazine.Approved, Withdrawn
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
TiaprideTiapride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Methotrimeprazine.Approved
TiletamineTiletamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
TilidineTilidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
TimololThe metabolism of Timolol can be decreased when combined with Methotrimeprazine.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Methotrimeprazine.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Methotrimeprazine.Approved, Investigational
TizanidineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Methotrimeprazine.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Tolfenamic Acid.Approved, Investigational
TolterodineThe metabolism of Tolterodine can be decreased when combined with Methotrimeprazine.Approved, Investigational
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ToremifeneMethotrimeprazine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Methotrimeprazine.Approved, Investigational
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
TranilastThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Tranilast.Approved, Investigational
TranylcypromineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
TrazodoneTrazodone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
TretoquinolMethotrimeprazine may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
Tricaine methanesulfonateTricaine methanesulfonate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
TrichloroethyleneTrichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
TrifluperidolTrifluperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
TriflupromazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the antihypertensive activities of Methotrimeprazine.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Trimethadione.Approved
TrimethoprimThe serum concentration of Methotrimeprazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Methotrimeprazine.Investigational, Withdrawn
TromethamineTromethamine can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TulobuterolMethotrimeprazine may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Methotrimeprazine.Approved, Investigational
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Methotrimeprazine.Approved
UrapidilUrapidil may increase the antihypertensive activities of Methotrimeprazine.Investigational
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Methotrimeprazine.Approved, Investigational
Valproic AcidValproic Acid may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
VandetanibMethotrimeprazine may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the hypotensive activities of Methotrimeprazine.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Methotrimeprazine.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Methotrimeprazine.Approved
VeraliprideVeralipride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
VerapamilMethotrimeprazine may increase the antihypertensive activities of Verapamil.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Methotrimeprazine.Approved, Investigational
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
VilanterolMethotrimeprazine may decrease the vasoconstricting activities of Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Methotrimeprazine.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Methotrimeprazine.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Methotrimeprazine.Approved, Investigational
VinpocetineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Vinpocetine.Investigational
Vinyl etherVinyl ether may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
VortioxetineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Methotrimeprazine is combined with WIN 55212-2.Experimental
XamoterolMethotrimeprazine may decrease the vasoconstricting activities of Xamoterol.Experimental
XenonXenon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Experimental
XylazineXylazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
XylometazolineMethotrimeprazine may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
YohimbineThe metabolism of Yohimbine can be decreased when combined with Methotrimeprazine.Approved, Investigational, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Methotrimeprazine.Approved, Investigational
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Illicit, Investigational
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ZolazepamZolazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Methotrimeprazine.Approved, Investigational
ZolpidemZolpidem may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
ZotepineZotepine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational, Withdrawn
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
Food Interactions
  • Take with food to reduce irritation.

References

Synthesis Reference

Christian Berger, "Process for preparing levomepromazine hydrogen maleate." U.S. Patent US4798895, issued January 17, 1989.

US4798895
General References
  1. Link [Link]
External Links
Human Metabolome Database
HMDB0015474
KEGG Drug
D00403
KEGG Compound
C07192
PubChem Compound
72287
PubChem Substance
46507223
ChemSpider
65239
BindingDB
50418049
ChEBI
6838
ChEMBL
CHEMBL1764
PharmGKB
PA164743234
Wikipedia
Levomepromazine
ATC Codes
N05AA02 — Levomepromazine
AHFS Codes
  • 28:16.08.24 — Phenothiazines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3Unknown StatusTreatmentPsychosis Nos/Other1
Not AvailableActive Not RecruitingTreatmentSchizophrenia Relapse1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral2 mg
TabletOral25 mg
TabletOral5 mg
TabletOral50 mg
SolutionOral5 mg
SolutionIntramuscular; Intravenous25 mg
Liquid; solution / dropsOral40 mg
Prices
Unit descriptionCostUnit
Nozinan 25 mg/ml3.6USD ml
Apo-Methoprazine 50 mg Tablet0.4USD tablet
Apo-Methoprazine 25 mg Tablet0.27USD tablet
Apo-Methoprazine 5 mg Tablet0.1USD tablet
Apo-Methoprazine 2 mg Tablet0.07USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility20 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.68HANSCH,C ET AL. (1995)
logS-4.22ADME Research, USCD
pKa9.19SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.00525 mg/mLALOGPS
logP4.84ALOGPS
logP4.25ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)9.42ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area15.71 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity99.83 m3·mol-1ChemAxon
Polarizability36.77 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9857
Blood Brain Barrier+0.9935
Caco-2 permeable+0.6694
P-glycoprotein substrateSubstrate0.6805
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.8571
Renal organic cation transporterNon-inhibitor0.5132
CYP450 2C9 substrateNon-substrate0.7511
CYP450 2D6 substrateSubstrate0.5363
CYP450 3A4 substrateSubstrate0.6056
CYP450 1A2 substrateInhibitor0.6953
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.5432
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5633
Ames testNon AMES toxic0.5562
CarcinogenicityNon-carcinogens0.9182
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5064 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.932
hERG inhibition (predictor II)Inhibitor0.8488
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-056r-9356000000-bb17e4980980d336d337
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-004i-0009000000-292add600a1d733c3662
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-004i-0319000000-9bcdb870e16f29c42cc7
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udi-2920000000-f73fff6b08acc61ea5b7
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0zfr-6920000000-dc5968beb0d112813d55
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-9410000000-0d1f6734452bedc68d3f
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-0udi-0910000000-10fe32fa41981fcda652

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / Anisoles / Alkyl aryl ethers / 1,4-thiazines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Anisole / Tertiary aliphatic/aromatic amine / Alkyl aryl ether / Para-thiazine / Benzenoid / Tertiary aliphatic amine
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines, tertiary amine (CHEBI:6838)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD5
Uniprot ID
P21918
Uniprot Name
D(1B) dopamine receptor
Molecular Weight
52950.5 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716]
  2. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716]
  2. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716]
  2. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716]
  2. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716]
  2. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716]
  3. Tsukamoto T, Asakura M, Hirata N, Imafuku J, Matsui H, Hasegawa K: Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91. [PubMed:6149771]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716]
  3. Tsukamoto T, Asakura M, Hirata N, Imafuku J, Matsui H, Hasegawa K: Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91. [PubMed:6149771]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205]
  2. Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. [PubMed:2870716]
  3. Tsukamoto T, Asakura M, Hirata N, Imafuku J, Matsui H, Hasegawa K: Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91. [PubMed:6149771]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine. Curr Med Res Opin. 2004 Dec;20(12):1877-81. [PubMed:15701205]

Drug created on July 10, 2007 12:38 / Updated on June 18, 2018 06:30